Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Extension in Psoriasis
NCT01544595Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2012
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Jun 2012; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01544595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01544595.